Evidence map›Paper›PMID 33861434›Full record

Trial reportAdvances in experimental medicine and biology2021

The Effect of Curcumin Phytosome on the Treatment of Patients with Non-alcoholic Fatty Liver Disease: A Double-Blind, Randomized, Placebo-Controlled Trial.

Seyed Reza Mirhafez, Mohsen Azimi-Nezhad, Maryam Dehabeh, Mitra Hariri, Ronika Danesh Naderan, Ali Movahedi, Mohammed Abdalla, Thozhukat Sathyapalan, Amirhossein Sahebkar

Abstract readRandomized Controlled Trial
PubMed Publisher
In one paragraph

Trial report in Advances in experimental medicine and biology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 37 papers, 4 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
37citing papers in PubMed, 4 pooled it
48.1field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

37 citing papers in PubMed, 4 syntheses or guidelines pooled it, 56 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Trial
  6. Trial
  7. Review
  8. Review
  9. Review
  10. Clinical Potential ofFoods (Basel, Switzerland) · 2025
    Review
  11. Article
  12. Review
  13. Review
  14. Article
  15. Review
  16. Review
  17. Enzyme-TreatedFoods (Basel, Switzerland) · 2024
    Article
  18. Review
  19. Article
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 5 institutions in 3 countries.

Seyed Reza MirhafezNoncommunicable Diseases Research Center, Neyshabur University of Medical Sciences, Neyshabur, Iran. mirhafez@nums.ac.ir.
Mohsen Azimi-NezhadNoncommunicable Diseases Research Center, Neyshabur University of Medical Sciences, Neyshabur, Iran.
Maryam DehabehNoncommunicable Diseases Research Center, Neyshabur University of Medical Sciences, Neyshabur, Iran.
Mitra HaririNoncommunicable Diseases Research Center, Neyshabur University of Medical Sciences, Neyshabur, Iran.
Ronika Danesh NaderanNoncommunicable Diseases Research Center, Neyshabur University of Medical Sciences, Neyshabur, Iran.
Ali MovahediDepartment of Anesthesia and Operating Room Nursing, Neyshabur University of Medical Sciences, Neyshabur, Iran.
Mohammed AbdallaAcademic Diabetes, Endocrinology and Metabolism, Hull York Medical School, University of Hull, Hull, UK.
Thozhukat SathyapalanAcademic Diabetes, Endocrinology and Metabolism, Hull York Medical School, University of Hull, Hull, UK.
Amirhossein SahebkarApplied Biomedical Research Center, Mashhad University of Medical Sciences, Mashhad, Iran. sahebkara@mums.ac.ir.
University of Neyshabur · IRNon-Communicable Diseases Research CenterHull York Medical School · GBPolish Mother’s Memorial Hospital Research Institute · PLUniversity of Hull · GB

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Non-alcoholic fatty liver disease (NAFLD) is a global health problem with increasing prevalence among overweight and obese patients. It is strongly associated with conditions of insulin resistance including type 2 diabetes mellitus (T2DM) and obesity. It has detrimental consequences ranged from simple steatosis to irreversible hepatic fibrosis and cirrhosis. Curcumin is a dietary polyphenol with potential effect in improving NAFLD. Therefore, the aim of this trial was to examine the effect of curcumin supplementation on various aspects of NAFLD. In this trial, a total number of 80 patients were randomised to receive either curcumin at 250 mg daily or placebo for 2 months. Lipid profiles, hepatic enzymes, anthropometric indices and hepatic fat mass were assessed at the baseline and the end of the trial, and compared within the groups. The grade of hepatic steatosis, and serum aspartate aminotransferase (AST) levels were significantly reduced in the curcumin group (p = 0.015 and p = 0.007, respectively) compared to the placebo. There was also a significant reduction in high density lipoprotein (HDL) levels and anthropometric indices in both groups with no significant differences between the two groups. Low dose phospholipid curcumin supplementation each day for 2 months showed significant reduction in hepatic steatosis and enzymes in patients with NAFLD compared to placebo. Further studies of longer duration and higher dosages are needed to assess its effect on other parameters of NAFLD including cardiovascular risk.

Indexed as

CurcuminDiabetes Mellitus, Type 2Non-alcoholic Fatty Liver DiseaseAspartate AminotransferasesDouble-Blind MethodHumansAspartate AminotransferasesCurcuminCurcuminNAFLDNASHNon-alcoholic fatty liver diseasePhytosomeTurmeric

Identifiers

PMID33861434
OpenAlexW3156551633

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.